Trial Profile
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms DUO
- Sponsors Ferring Pharmaceuticals
- 19 Feb 2022 Preliminary results (n=124) presented at the 2022 Genitourinary Cancers Symposium
- 13 Sep 2021 Results of a preliminary analysis presented at the 116th Annual Meeting of the American Urological Association
- 25 Feb 2019 Status changed from active, no longer recruiting to completed.